 |
 |
|||||
 |
 |
 |
||||
 |
 |
 |
 |
 |
 |
  |
 |
||||||
Current study projects
The following list briefly describes our current projects.
If you as a patient are interested in a study please get in touch with us by the contact button.
| Name of study | Indication | Description | Patients | Status |
|---|---|---|---|---|
IBS-D |
Irritable Bowel Syndrome with Diarrhoea |
Double-blind, randomised, placebo-controlled, parallel group study to evaluate the effect of a 4-week treatment, 1, 3 or 10mg/d oral treatment Ibodutant vs. Placebo. |
18 -70 years |
Currently recruiting patients |
| Colitis ulcerosa | Mild to moderate distal Colitis Ulcerosa | 2-week randomised, double-blind, placebo-controlled, clinical parallel group study with increasing doses to evaluate safety, agree-ableness of a new natural drug, rectal treatment in the evening. | 18 – 75 years |
Currently recruiting patients |
| Acute Knee Injury | Acute cartilage injury of knee within the past 4 to 12 weeks | Clinical research study to test the safety and effectiveness of an experimental drug, placebo-controlled, i.a. injection, MRT to measure the injury. | 18 – 45 years | Currently recruiting patients |
| Chronic Unspecified Back Pain | Back pain for at least 3 months, in rest and movement, without basic cause |
Local treatment of an approved medication, placebo-controlled. | 18 – 75 years |
Currently recruiting patients |
| Constipation | Patients with moderate to severe pain and constipation due to daily therapy with strong analgesic |
Parallel-group, double-blind, placebo-controlled study to approve a new strong analgesic. |
18 years and above |
Currently recruiting patients |
| Vaccination against Zoster | Prophylaxis to avoid Herpes Zoster | Approved Vaccine against Herpes Zoster, i.m. or subcutaneous vaccination, no placebo. | 40 years and above | Currently recruiting patients |
| COPD | Smoker and Ex-Smoker with COPD | A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a new inhalation powder and the individual components once-daily in subjects with known Chronic Obstructive Pulmonary Disease. | 40 years and above | Currently recruiting patients |
|
|
|||
| Chronic Idiopathic Urticaria | Chronic Idiopathic Urticaria, symptomatic despite antihistamine treatment (H1) | A Phase III, multicenter, randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy, response duration and safety of Xolair® (Omalizumab) in patients with Chronic Idiopathic Urticaria (CIU) who remain symptomatic despite antihistamine treatment (H1/H2). | 12 - 75 years | Soon recruiting patients |
| Hypertension | Essential Hypertension Grade 2/ 3, under treatment with 1 – 3 agents |
A Phase-3 randomized, double-blind, efficacy and safety study evaluating the fixed dose |
18 years and above | Soon recruiting patients |
| Depression | Primary Major Depression | Multicenter, randomized, double-blind, double-dummy, flexible-dose, placebo-controlled parallel study in the relapse prevention of stabilized patients, in remission, with MDD. | 18 years and above | Soon recruiting patients |
| Hypersensitivity to Grass Pollen | Hypersensitivity to Grass Pollen with or without intermittent Asthma. | Randomized, double-blind, parallel group, multicenter study to evaluate the efficacy and safety of four doses of Depigoid® Phleum in Patients with allergic rhinitis and/or rhino-conjunctivitis with or without intermittent asthma. No placebo. | 18 -70 years | Soon recruiting patients |
| Psoriasis | Plaque-type Psoriasis | Phase 2 multicenter, randomized, placebo-controlled dose-ranging trial evaluating the efficacy and safety of a new Biological in the treatment of subjects with moderate to severe Plaque-type Psoriasis. | 18 years and above | Soon recuiting patients |
| Name of study | Indication | Description | Patients | Status |
Home
Current studies
Clinical Research Hamburg GmbH · Rahlstedter Bahnhofstr. 33 · 22143 Hamburg
Phone: +49 (0) 40 631297-0 · Fax: +49 (0) 40 631297-19 · Email: info@crh-hamburg.de
